| Autor: |
Sanjeev Krishna, Rachel L Byrne, Michael H. Johnson, Ana I Cubas-Atienzar, Alice J. Fraser, Nicholas M Eckersley, Irene M. Monahan, James Schouten, Qinxue Hu, Kesja Klekotko, Stefanie Menzies, David J. Clark, Daniel M. Forton, Linda Hadcocks, Martina Cusinato, Luis E. Cuevas, Daniela E. Kirwan, Gerhard Nebe-von-Caron, Gala Garrod, Catherine Moore, Emily R. Adams, Benedict M O Davies, Tim Planche, Amadou A. Sall, Paul A. Davis, Joseph R Fitchett, Josephine Mensah-Kane, Henry M. Staines, Michael Cocozza, Sophie I Owen, Grant A Kay, Christopher T Williams, Chris Sainter, Derek C. Macallan, Yolanda Augustin, Zawditu Lewis, Kevin Woolston, Annelyse Duvoix, John T. Wilkins, Mark M. Davis |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 27, Iss 1, Pp 85-91 (2021) |
| ISSN: |
1080-6059 |
| Popis: |
We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29-May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS-CoV-2 infection. We measured IgG against SARS-CoV-2 and compared antibody levels with patient outcomes, demographic information, and laboratory characteristics. We found that 2.0%-8.5% of persons did not seroconvert 3-6 weeks after infection. Persons who seroconverted were older, were more likely to have concurrent conditions, and had higher levels of inflammatory markers. Non-White persons had higher antibody concentrations than those who identified as White; these concentrations did not decline during follow-up. Serologic assay results correlated with disease outcome, race, and other risk factors for severe SARS-CoV-2 infection. Serologic assays can be used in surveillance to clarify the duration and protective nature of humoral responses to SARS-CoV-2 infection. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
